NEWTON, Mass., Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ...
Hosted on MSN
Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion
CEO Richard Paulson announced that the Phase 3 SENTRY trial in JAKi-naïve myelofibrosis patients "has passed its prespecified futility analysis and continues as planned without modifications." Paulson ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results